Randomized Clinical Trial: Impact of Oral Administration of Saccharomyces boulardii on Gene Expression of Intestinal Cytokines in Patients Undergoing Colon Resection

Journal of Parenteral and Enteral Nutrition

Volumn 40, Issue 8, 2016, Pages 1114-1121

  Consoli, Marcella Lobato D ^a   Da Silva, Raphael Steinberg ^a   Nicoli, Jacques Robert ^a   Bruña Romero, Oscar ^a   Da Silva, Rodrigo Gomes ^a   De Vasconcelos Generoso, Simone ^a   Correia, Maria Isabel T D ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

colon; intestinal cytokines; probiotic; surgery

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23P19; INTERLEUKIN 6; MESSENGER RNA; PROBIOTIC AGENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON MUCOSA; COLON RESECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM FISTULA; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INCIDENCE; INFECTION RATE; INTESTINE FLORA; LENGTH OF STAY; MALE; MORBIDITY; PERINEAL FISTULA; PERINEAL INFECTION; PERIOPERATIVE PERIOD; POSTOPERATIVE INFECTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SACCHAROMYCES BOULARDII; SURGICAL MORTALITY; SURGICAL PATIENT; URINARY TRACT INFECTION; ABDOMINAL SURGERY; ADOLESCENT; BODY MASS; COLON; GENETICS; INTESTINE; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; SURGERY; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; COLON; CYTOKINES; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DOWN-REGULATION; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINAL MUCOSA; INTESTINES; LENGTH OF STAY; MALE; MIDDLE AGED; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROBIOTICS; SACCHAROMYCES BOULARDII; YOUNG ADULT;

EID: 84995467524     PISSN: 01486071     EISSN: 19412444     Source Type: Journal    
DOI: 10.1177/0148607115584387     Document Type: Article

References (37)

1. Tran KT, Smeenk HG, van Eijck CH, et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg. 2004; 240 (5): 738-745.
2. Liu Z, Qin H, Yang Z, et al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery-a double-blind study. Aliment Pharmacol Ther. 2011; 33 (1): 50-63.
3. Gianotti L, Morelli L, Galbiati F, et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 2010; 16 (2): 167-175.
4. Food and Agriculture Organization (FAO)/World Health Organization (WHO). Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001. www.fao.org. Accessed July 20, 2014.
5. McFarland LV., Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010; 16 (18): 2202-2222.
6. Tasteyre A, Barc MC, Karjalainen T, Bourlioux P, Collignon A., Inhibition of in vitro cell adherence of Clostridium difficile by. Saccharomyces boulardii. Microb Pathog. 2002; 32 (5): 219-225.
7. Geyik MF, Aldemir M, Hosoglu S, et al. The effects of Saccharomyces boulardii on bacterial translocation in rats with obstructive jaundice. Ann R Coll Surg Engl. 2006; 88 (2): 176-180.
8. Berg R, Bernasconi P, Fowler D, Gautreaux M., Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of. Saccharomyces boulardii. J Infect Dis. 1993; 168 (5): 1314-1318.
9. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993; 104 (4): 1108-1115.
10. Brandao RL, Castro IM, Bambirra EA, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and. Saccharomyces cerevisiae. Appl Environ Microbiol. 1998; 64 (2): 564-568.
11. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P., Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli -infected T84 cells. Infect Immun. 2000; 68 (10): 5998-6004.
12. Generoso SV, Viana ML, Santos RG, et al. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed. Saccharomyces boulardii. Eur J Nutr. 2011; 50 (4): 261-269.
13. Schroeder B, Winckler C, Failing K, Breves G., Studies on the time course of the effects of the probiotic yeast Saccharomyces boulardii on electrolyte transport in pig jejunum. Dig Dis Sci. 2004; 49 (7-8): 1311-1317.
14. Generoso SV, Viana M, Santos R, et al. Saccharomyces cerevisiae strain UFMG 905 protects against bacterial translocation, preserves gut barrier integrity and stimulates the immune system in a murine intestinal obstruction model. Arch Microbiol. 2010; 192 (6): 477-484.
15. Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ., The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci. 2009; 54 (2): 255-263.
16. Kinross JM, Markar S, Karthikesalingam A, et al. A meta-analysis of probiotic and synbiotic use in elective surgery: does nutrition modulation of the gut microbiome improve clinical outcome? JPEN J Parenter Enteral Nutr. 2013; 37 (2): 243-253.
17. Correia MITD, Liboredo JC, Consoli MLD,. The role of probiotics in gastrointestinal surgery. Nutrition. 2012; 28 (3): 230-234.
18. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J., qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007; 8 (2): R19.
19. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009; 250 (2): 187-196.
20. Lee YK, Mazmanian SK., Has the microbiota played a critical role in the evolution of the adaptive immune system? Science. 2010; 330 (6012): 1768-1773.
21. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C., An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods. 2001; 25 (4): 386-401.
22. Overbergh L, Giulietti A, Valckx D, Decallonne R, Bouillon R, Mathieu C., The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech. 2003; 14 (1): 33-43.
23. Lammers KM, Vergopoulos A, Babel N, et al. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Inflamm Bowel Dis. 2005; 11 (5): 447-454.
24. Iwakura Y, Ishigame H., The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006; 116 (5): 1218-1222.
25. Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 1998; 160 (7): 3513-3521.
26. Kolls JK, Khader SA., The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev. 2010; 21 (6): 443-448.
27. Korn T, Bettelli E, Oukka M, Kuchroo VK., IL-17 and Th17 cells. Annu Rev Immunol. 2009; 27: 485-517.
28. Sarra M, Pallone F, Macdonald TT, Monteleone G., IL-23/IL-17 axis in IBD. Inflamm Bowel Dis. 2010; 16 (10): 1808-1813.
29. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK., IL-17 cytokine family. J Allergy Clin Immunol. 2004; 114 (6): 1265-1274.
30. Nickoloff BJ, Qin JZ, Nestle FO., Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol. 2007; 33 (1-2): 45-56.
31. Bouma G, Strober W., The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003; 3 (7): 521-533.
32. Liu ZH, Huang MJ, Zhang XW, et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am J Clin Nutr. 2013; 97 (1): 117-126.
33. Zhang JW, Du P, Gao J, Yang BR, Fang WJ, Ying CM., Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci. 2012; 343 (3): 199-205.
34. Sugawara G, Nagino M, Nishio H, et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg. 2006; 244 (5): 706-714.
35. Kinross J, Warren O, Silk D, Darzi A., Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized control trial. Ann Surg. 2007; 245 (6): 1000.
36. Reddy BS, Macfie J, Gatt M, Larsen CN, Jensen SS, Leser TD., Randomized clinical trial of effect of synbiotics, neomycin and mechanical bowel preparation on intestinal barrier function in patients undergoing colectomy. Br J Surg. 2007; 94 (5): 546-554.
37. Brandt KG, Sampaio MMSC, Miuki CJ., Importance of the intestinal microflora. Pediatria (São Paulo). 2006; 28 (2): 117-127.